Royalty Pharma (RPRX) EPS (Diluted) (QoQ) (2020 - 2026)
Powered by 
Analysis
Royalty Pharma (RPRX) EPS (Diluted) (QoQ) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.78 Bn | 130.92 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.50 Bn | 77.51 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn |
| 4 | Moderna | 58.06 Bn | 52.92 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - |
| 6 | BeOne Medicines | 40.04 Bn | 34.94 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - |
| 9 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 10 | Incyte | 25.61 Bn | 21.07 Bn | 1.57 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -82.60% |
| Mar 31, 2026 | 33.36% |
| Dec 31, 2025 | -20.57% |
| Sep 30, 2025 | 381.83% |
| Jun 30, 2025 | -78.08% |
| Mar 31, 2025 | 33.53% |
| Dec 31, 2024 | -58.63% |
| Sep 30, 2024 | 317.77% |
| Jun 30, 2024 | 4,653.28% |
| Mar 31, 2024 | -100.60% |
| Dec 31, 2023 | 486.10% |
| Sep 30, 2023 | -64.98% |
| Jun 30, 2023 | -30.83% |
| Mar 31, 2023 | 160.19% |
| Dec 31, 2022 | -483.72% |
| Sep 30, 2022 | -55.16% |
| Jun 30, 2022 | 283.80% |
| Mar 31, 2022 | 63.03% |
| Dec 31, 2021 | -64.58% |
| Sep 30, 2021 | -72.51% |